Press "Enter" to skip to content

New Publication Shows Different Result of Risk Classification between GenesWell BCT and Oncotype DX in Breast Cancer Patients 50 Years Old or Younger. – PRNewswire

admin 0

New Publication Shows Different Result of Risk Classification between GenesWell BCT and Oncotype DX in Breast Cancer Patients 50 Years Old or Younger.  PRNewswire

SEOUL, South Korea, Aug. 12, 2019 /PRNewswire/ — Gencurix, Inc., a company dedicated in development and market of innovative molecular diagnostics, …

“colorectal cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *